Alder Biopharmaceuticals, Inc.. (ALDR) NASDAQ
$18.88 - (-)
Market Cap: -
As of 10/21/19 04:00 PM EDT. Market closed.
Alder Biopharmaceuticals, Inc.. (ALDR)
NASDAQ
$18.88
- (-)
Market Cap: -
As of 10/21/19 04:00 PM EDT. Market closed.
Add to Portfolio
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), ... read more
COMPANY PROFILE
Sector
Health Technology
Industry
Biotechnology
CEO Compensation (Base)
$187,480
CEO Compensation (Total)
$3.16M
Sector
Health Technology
Industry
Biotechnology
CEO
Robert W. Azelby
CEO Compensation (Base)
$187,480
CEO Compensation (Total)
$3.16M
URL
Address
11804 North Creek Parkway South, WA, Bothell, 98011.
PRICE CHART FOR ALDER BIOPHARMACEUTICALS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
-
Days Range
- - -
52 week range
$8.39 - $19.12
Volume
0
Avg. Volume (30 days)
6,665,768
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
Open
-
Previous Close
-
Days Range
- - -
52 week range
$8.39 - $19.12
Volume
0
Avg. Volume (30 days)
6,665,768
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
0
FINANCIAL STATEMENTS FOR ALDER BIOPHARMACEUTICALS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ALDER BIOPHARMACEUTICALS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| STRECK PAUL | Chief Medical Officer | Oct 11, 2019 | Option Exercise | $9.20 | 1,390 | 12,788 | 1,390 | Oct 24, 2019, 07:28 PM |
| STRECK PAUL | Chief Medical Officer | Oct 22, 2019 | Option Exercise | $18.00 | 1,390 | 25,020 | 0 | Oct 24, 2019, 07:28 PM |
| Lavelle Erin | Chief Operating Officer | Oct 22, 2019 | Option Exercise | $18.00 | 16,092 | 289,656 | 0 | Oct 24, 2019, 07:12 PM |
| Bucher James B | EVP & General Counsel | Oct 11, 2019 | Option Exercise | $9.20 | 904 | 8,317 | 12,058 | Oct 24, 2019, 07:10 PM |
| Bucher James B | EVP & General Counsel | May 31, 2019 | Option Exercise | $9.20 | 1,345 | 12,370 | 11,154 | Oct 24, 2019, 07:10 PM |
| Bucher James B | EVP & General Counsel | Oct 22, 2019 | Option Exercise | $18.00 | 27,677 | 498,186 | 0 | Oct 24, 2019, 07:10 PM |
| Hassler Randal | EVP, Pharmaceutical Ops. | Oct 22, 2019 | Option Exercise | $18.00 | 19,780 | 356,040 | 0 | Oct 24, 2019, 07:09 PM |
| Smith Jeffrey T L | Managing Director | Oct 22, 2019 | Option Exercise | $18.00 | 21,502 | 387,036 | 0 | Oct 24, 2019, 07:07 PM |
| YARNO WENDY L | Director | Oct 22, 2019 | Option Exercise | $18.00 | 5,000 | 90,000 | 0 | Oct 24, 2019, 07:05 PM |
| SIEGALL CLAY B | Director | Oct 22, 2019 | Option Exercise | $18.00 | 31,714 | 570,852 | 0 | Oct 24, 2019, 07:03 PM |
| Montgomery Alan Bruce | Director | Oct 22, 2019 | Option Exercise | $18.00 | 9,628 | 173,304 | 0 | Oct 24, 2019, 06:58 PM |
| Smith Jeffrey T L | Managing Director | Sep 16, 2019 | Option Exercise | $4.15 | 32,728 | 135,902 | 38,000 | Sep 18, 2019, 04:45 PM |
| Smith Jeffrey T L | Managing Director | Sep 16, 2019 | Sale | $18.44 | 32,728 | 603,504 | 5,272 | Sep 18, 2019, 04:45 PM |
| Hassler Randal | EVP, Pharmaceutical Ops. | Apr 25, 2019 | Sale | $13.85 | 1,738 | 24,067 | 5,434 | Apr 25, 2019, 06:55 PM |
| Benedict Larry | EVP and PAO | Apr 25, 2019 | Sale | $13.65 | 1,734 | 23,662 | 39,728 | Apr 25, 2019, 06:53 PM |
| Smith Jeffrey T L | Managing Director | Apr 25, 2019 | Option Exercise | $13.73 | 4,847 | 66,526 | 5,272 | Apr 25, 2019, 06:51 PM |
| Lavelle Erin | Chief Operating Officer | Apr 25, 2019 | Sale | $13.67 | 1,434 | 19,599 | 4,408 | Apr 25, 2019, 06:49 PM |
| Bucher James B | EVP & General Counsel | Apr 25, 2019 | Sale | $13.85 | 1,897 | 26,281 | 9,809 | Apr 25, 2019, 06:43 PM |
| Redmile Group, LLC | Director | Mar 04, 2019 | Option Exercise | $11.50 | 1,739,130 | 19,999,995 | 8,244,896 | Mar 06, 2019, 04:24 PM |
| Latham John A | Chief Scientific Officer | Nov 30, 2018 | Option Exercise | $9.35 | 487 | 4,553 | 244,180 | Feb 08, 2019, 04:47 PM |
| Bucher James B | EVP & General Counsel | Nov 30, 2018 | Option Exercise | $9.35 | 273 | 2,553 | 3,896 | Feb 08, 2019, 04:43 PM |
| Benedict Larry | EVP and PAO | Nov 30, 2018 | Option Exercise | $9.35 | 954 | 8,920 | 34,407 | Feb 08, 2019, 04:41 PM |
| Benedict Larry | EVP and PAO | May 31, 2018 | Option Exercise | $9.35 | 1,319 | 12,333 | 33,453 | Feb 08, 2019, 04:41 PM |
| Smith Jeffrey T L | Managing Director | Dec 03, 2018 | Option Exercise | $0.99 | 5,044 | 4,994 | 5,875 | Dec 04, 2018, 06:39 PM |
| Smith Jeffrey T L | Managing Director | Dec 03, 2018 | Sale | $13.84 | 5,044 | 69,826 | 831 | Dec 04, 2018, 06:39 PM |
| Bucher James B | Sr. VP & General Counsel | May 31, 2018 | Option Exercise | $9.35 | 2,000 | 18,700 | 3,623 | Nov 27, 2018, 05:35 PM |
| Smith Jeffrey T L | Managing Director | Nov 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Nov 05, 2018, 05:47 PM |
| Smith Jeffrey T L | Managing Director | Nov 01, 2018 | Sale | $13.42 | 5,040 | 67,637 | 831 | Nov 05, 2018, 05:47 PM |
| Latham John A | Chief Scientific Officer | Nov 01, 2018 | Option Exercise | $9.12 | 25,002 | 227,954 | 268,695 | Nov 05, 2018, 05:43 PM |
| Latham John A | Chief Scientific Officer | Nov 01, 2018 | Sale | $13.42 | 25,002 | 335,589 | 245,012 | Nov 05, 2018, 05:43 PM |
| Smith Jeffrey T L | Managing Director | Oct 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Oct 03, 2018, 06:33 PM |
| Smith Jeffrey T L | Managing Director | Oct 01, 2018 | Sale | $15.54 | 5,040 | 78,329 | 2,831 | Oct 03, 2018, 06:33 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2018 | Option Exercise | $4.36 | 24,999 | 109,108 | 268,692 | Oct 03, 2018, 06:31 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2018 | Sale | $15.44 | 24,999 | 386,006 | 250,247 | Oct 03, 2018, 06:31 PM |
| Smith Jeffrey T L | Managing Director | Sep 04, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Sep 06, 2018, 05:08 PM |
| Smith Jeffrey T L | Managing Director | Sep 04, 2018 | Sale | $18.00 | 5,040 | 90,699 | 831 | Sep 06, 2018, 05:08 PM |
| Latham John A | Chief Scientific Officer | Sep 04, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Sep 06, 2018, 05:05 PM |
| Latham John A | Chief Scientific Officer | Sep 04, 2018 | Sale | $17.99 | 24,999 | 449,680 | 243,693 | Sep 06, 2018, 05:05 PM |
| Smith Jeffrey T L | Managing Director | Aug 01, 2018 | Option Exercise | $0.99 | 5,040 | 4,990 | 5,871 | Aug 02, 2018, 05:48 PM |
| Smith Jeffrey T L | Managing Director | Aug 01, 2018 | Sale | $19.54 | 5,040 | 98,489 | 1,811 | Aug 02, 2018, 05:48 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Aug 02, 2018, 05:40 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2018 | Sale | $19.55 | 24,999 | 488,768 | 243,693 | Aug 02, 2018, 05:40 PM |
| Smith Jeffrey T L | Managing Director | Jul 02, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | Jul 03, 2018, 05:28 PM |
| Smith Jeffrey T L | Managing Director | Jul 02, 2018 | Sale | $15.49 | 12,161 | 188,364 | 831 | Jul 03, 2018, 05:28 PM |
| Latham John A | Chief Scientific Officer | Jul 02, 2018 | Option Exercise | $3.46 | 24,999 | 86,622 | 268,692 | Jul 03, 2018, 05:22 PM |
| Latham John A | Chief Scientific Officer | Jul 02, 2018 | Sale | $15.48 | 24,999 | 387,002 | 243,693 | Jul 03, 2018, 05:22 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2018 | Option Exercise | $4.37 | 24,999 | 109,121 | 268,692 | Jun 05, 2018, 05:43 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2018 | Sale | $17.85 | 24,999 | 446,356 | 248,492 | Jun 05, 2018, 05:43 PM |
| Smith Jeffrey T L | Managing Director | Jun 01, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | Jun 05, 2018, 05:41 PM |
| Smith Jeffrey T L | Managing Director | Jun 01, 2018 | Sale | $17.85 | 12,161 | 217,127 | 1,931 | Jun 05, 2018, 05:41 PM |
| Litton Mark James | Chief Business Officer | Jun 01, 2018 | Option Exercise | $0.99 | 22,727 | 22,500 | 124,916 | Jun 05, 2018, 05:40 PM |
| Litton Mark James | Chief Business Officer | Jun 01, 2018 | Sale | $17.84 | 22,727 | 405,412 | 106,663 | Jun 05, 2018, 05:40 PM |
| Smith Jeffrey T L | Managing Director | May 16, 2018 | Option Exercise | $1.38 | 12,161 | 16,739 | 12,992 | May 18, 2018, 05:57 PM |
| Smith Jeffrey T L | Managing Director | May 16, 2018 | Sale | $15.03 | 12,161 | 182,758 | 831 | May 18, 2018, 05:57 PM |
| Latham John A | Chief Scientific Officer | Nov 30, 2017 | Option Exercise | $9.35 | 472 | 4,413 | 243,208 | Dec 18, 2017, 06:28 PM |
| Latham John A | Chief Scientific Officer | May 31, 2017 | Option Exercise | $13.09 | 333 | 4,359 | 242,736 | Dec 18, 2017, 06:28 PM |
| Bucher James B | Sr. VP & General Counsel | Nov 30, 2017 | Option Exercise | $9.35 | 1,623 | 15,175 | 1,623 | Dec 18, 2017, 06:25 PM |
| Litton Mark James | Chief Business Officer | Nov 13, 2017 | Option Exercise | $1.65 | 16,519 | 27,256 | 116,451 | Nov 15, 2017, 05:54 PM |
| Litton Mark James | Chief Business Officer | Nov 13, 2017 | Sale | $10.80 | 16,519 | 178,486 | 99,932 | Nov 15, 2017, 05:54 PM |
| SIEGALL CLAY B | Director | Nov 01, 2017 | Option Exercise | $1.30 | 27,270 | 35,496 | 31,714 | Nov 03, 2017, 05:48 PM |
| Litton Mark James | Chief Business Officer | Oct 16, 2017 | Option Exercise | $1.65 | 16,520 | 27,258 | 116,452 | Oct 18, 2017, 06:20 PM |
| Litton Mark James | Chief Business Officer | Oct 16, 2017 | Sale | $12.33 | 16,520 | 203,703 | 99,932 | Oct 18, 2017, 06:20 PM |
| YARNO WENDY L | Director | Jul 18, 2017 | Buy | $10.00 | 5,000 | 50,000 | 5,000 | Jul 18, 2017, 07:52 PM |
| DOW STEPHEN M | Director | Jul 18, 2017 | Buy | $10.00 | 25,000 | 250,000 | 307,190 | Jul 18, 2017, 07:50 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 20, 2017 | Option Exercise | $0.99 | 585 | 579 | 1,416 | Jun 22, 2017, 06:12 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 20, 2017 | Sale | $20.00 | 585 | 11,700 | 831 | Jun 22, 2017, 06:12 PM |
| Schatzman Randall C | President and CEO | Feb 09, 2017 | Option Exercise | $1.65 | 30,000 | 49,500 | 145,172 | Feb 13, 2017, 06:10 PM |
| Schatzman Randall C | President and CEO | Feb 09, 2017 | Sale | $25.03 | 30,000 | 750,756 | 115,172 | Feb 13, 2017, 06:10 PM |
| Benedict Larry | EVP and PAO | Nov 30, 2016 | Option Exercise | $20.20 | 742 | 14,988 | 30,989 | Jan 31, 2017, 05:32 PM |
| Schatzman Randall C | President and CEO | Nov 30, 2016 | Option Exercise | $20.20 | 404 | 8,161 | 115,172 | Jan 31, 2017, 05:23 PM |
| Litton Mark James | Chief Business Officer | Jan 18, 2017 | Option Exercise | $1.65 | 1,498 | 2,472 | 101,430 | Jan 20, 2017, 06:38 PM |
| Litton Mark James | Chief Business Officer | Jan 18, 2017 | Sale | $23.10 | 1,498 | 34,599 | 99,932 | Jan 20, 2017, 06:38 PM |
| Litton Mark James | Chief Business Officer | Jan 09, 2017 | Option Exercise | $1.65 | 500 | 825 | 100,432 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 06, 2017 | Option Exercise | $1.34 | 6,800 | 9,113 | 106,732 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 05, 2017 | Option Exercise | $1.26 | 2,216 | 2,803 | 102,148 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 09, 2017 | Sale | $23.00 | 500 | 11,500 | 99,932 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 06, 2017 | Sale | $23.02 | 6,800 | 156,520 | 99,932 | Jan 09, 2017, 05:49 PM |
| Litton Mark James | Chief Business Officer | Jan 05, 2017 | Sale | $23.00 | 2,216 | 50,972 | 99,932 | Jan 09, 2017, 05:49 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,831 | Dec 05, 2016, 06:47 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2016 | Sale | $22.78 | 3,000 | 68,328 | 1,331 | Dec 05, 2016, 06:47 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2016 | Option Exercise | $1.65 | 3,636 | 5,999 | 246,039 | Dec 05, 2016, 06:46 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2016 | Sale | $22.78 | 3,636 | 82,812 | 242,903 | Dec 05, 2016, 06:46 PM |
| Latham John A | Chief Scientific Officer | Nov 09, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Nov 14, 2016, 06:32 PM |
| Latham John A | Chief Scientific Officer | Nov 09, 2016 | Sale | $30.18 | 10,000 | 301,839 | 242,200 | Nov 14, 2016, 06:32 PM |
| Schatzman Randall C | President and CEO | Nov 07, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 124,768 | Nov 09, 2016, 06:17 PM |
| Schatzman Randall C | President and CEO | Nov 07, 2016 | Sale | $25.16 | 10,000 | 251,605 | 114,768 | Nov 09, 2016, 06:17 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Nov 03, 2016, 06:39 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 01, 2016 | Sale | $24.34 | 3,000 | 73,032 | 400 | Nov 03, 2016, 06:39 PM |
| Litton Mark James | Chief Business Officer | Oct 17, 2016 | Sale | $27.50 | 6,000 | 164,998 | 26,000 | Oct 19, 2016, 05:51 PM |
| Benedict Larry | EVP and PAO | May 31, 2016 | Option Exercise | $8.50 | 2,000 | 17,000 | 30,247 | Oct 11, 2016, 04:56 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 03, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Oct 05, 2016, 07:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 03, 2016 | Sale | $31.14 | 3,000 | 93,415 | 702 | Oct 05, 2016, 07:02 PM |
| Schatzman Randall C | President and CEO | Oct 03, 2016 | Option Exercise | $1.26 | 8,181 | 10,349 | 122,949 | Oct 05, 2016, 06:54 PM |
| Schatzman Randall C | President and CEO | Oct 03, 2016 | Sale | $31.15 | 8,181 | 254,811 | 117,468 | Oct 05, 2016, 06:54 PM |
| Latham John A | Chief Scientific Officer | Oct 03, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Oct 05, 2016, 06:53 PM |
| Latham John A | Chief Scientific Officer | Oct 03, 2016 | Sale | $31.32 | 10,000 | 313,152 | 248,449 | Oct 05, 2016, 06:53 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Sep 06, 2016, 06:39 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2016 | Sale | $32.49 | 10,000 | 324,949 | 242,200 | Sep 06, 2016, 06:39 PM |
| Schatzman Randall C | President and CEO | Sep 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Sep 06, 2016, 06:36 PM |
| Schatzman Randall C | President and CEO | Sep 01, 2016 | Sale | $32.48 | 10,000 | 324,820 | 114,768 | Sep 06, 2016, 06:36 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Sep 06, 2016, 06:34 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2016 | Sale | $32.49 | 3,000 | 97,483 | 100 | Sep 06, 2016, 06:34 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 15, 2016 | Option Exercise | $1.65 | 3,000 | 4,950 | 3,000 | Aug 17, 2016, 06:55 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 15, 2016 | Sale | $31.17 | 3,000 | 93,512 | 0 | Aug 17, 2016, 06:55 PM |
| Schatzman Randall C | President and CEO | Aug 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Aug 03, 2016, 06:42 PM |
| Schatzman Randall C | President and CEO | Aug 01, 2016 | Sale | $31.15 | 10,000 | 311,513 | 119,600 | Aug 03, 2016, 06:42 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Aug 03, 2016, 06:33 PM |
| Latham John A | Chief Scientific Officer | Aug 01, 2016 | Sale | $31.19 | 10,000 | 311,948 | 245,806 | Aug 03, 2016, 06:33 PM |
| Latham John A | Chief Scientific Officer | Jul 26, 2016 | Option Exercise | $1.65 | 813 | 1,341 | 243,013 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 27, 2016 | Option Exercise | $1.65 | 9,187 | 15,159 | 251,387 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 26, 2016 | Sale | $30.00 | 813 | 24,392 | 242,200 | Jul 28, 2016, 06:37 PM |
| Latham John A | Chief Scientific Officer | Jul 27, 2016 | Sale | $30.15 | 9,187 | 277,023 | 242,200 | Jul 28, 2016, 06:37 PM |
| Schatzman Randall C | President and CEO | Jul 25, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Jul 27, 2016, 06:19 PM |
| Schatzman Randall C | President and CEO | Jul 25, 2016 | Sale | $28.08 | 10,000 | 280,805 | 114,768 | Jul 27, 2016, 06:19 PM |
| Litton Mark James | Chief Business Officer | Jul 12, 2016 | Option Exercise | $0.38 | 25,000 | 9,625 | 99,567 | Jul 14, 2016, 07:14 PM |
| Litton Mark James | Chief Business Officer | Jun 13, 2016 | Sale | $28.94 | 6,000 | 173,664 | 28,200 | Jun 15, 2016, 07:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 03, 2016 | Option Exercise | $1.26 | 16,090 | 20,354 | 16,090 | Jun 07, 2016, 07:32 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 03, 2016 | Sale | $30.20 | 16,090 | 485,933 | 4,805 | Jun 07, 2016, 07:32 PM |
| Schatzman Randall C | President and CEO | Jun 01, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 124,768 | Jun 03, 2016, 07:16 PM |
| Schatzman Randall C | President and CEO | Jun 01, 2016 | Sale | $29.65 | 10,000 | 296,544 | 116,733 | Jun 03, 2016, 07:16 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2016 | Option Exercise | $1.65 | 10,000 | 16,500 | 252,200 | Jun 03, 2016, 07:11 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2016 | Sale | $30.02 | 10,000 | 300,216 | 242,200 | Jun 03, 2016, 07:11 PM |
| Latham John A | Chief Scientific Officer | May 31, 2016 | Option Exercise | $1.37 | 33,599 | 46,003 | 275,799 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 27, 2016 | Option Exercise | $1.26 | 6,401 | 8,097 | 248,601 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 27, 2016 | Sale | $30.05 | 6,401 | 192,335 | 242,200 | Jun 01, 2016, 07:53 PM |
| Latham John A | Chief Scientific Officer | May 31, 2016 | Sale | $30.04 | 33,599 | 1,009,284 | 242,200 | Jun 01, 2016, 07:53 PM |
| Litton Mark James | Chief Business Officer | May 31, 2016 | Option Exercise | $0.38 | 19,720 | 7,592 | 94,287 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 27, 2016 | Option Exercise | $0.38 | 5,280 | 2,033 | 79,847 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 31, 2016 | Sale | $30.05 | 19,720 | 592,566 | 74,567 | Jun 01, 2016, 07:49 PM |
| Litton Mark James | Chief Business Officer | May 27, 2016 | Sale | $30.06 | 5,280 | 158,693 | 74,567 | Jun 01, 2016, 07:49 PM |
| Schatzman Randall C | President and CEO | May 23, 2016 | Option Exercise | $1.26 | 2,997 | 3,791 | 115,944 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 20, 2016 | Option Exercise | $1.26 | 2,986 | 3,777 | 115,933 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 24, 2016 | Option Exercise | $1.26 | 4,017 | 5,082 | 116,964 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 23, 2016 | Sale | $28.01 | 2,997 | 83,952 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 20, 2016 | Sale | $28.01 | 2,986 | 83,635 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | May 24, 2016 | Sale | $28.03 | 4,017 | 112,588 | 112,947 | May 24, 2016, 08:13 PM |
| Schatzman Randall C | President and CEO | Apr 15, 2016 | Option Exercise | $0.73 | 14,024 | 10,227 | 126,971 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 14, 2016 | Option Exercise | $0.38 | 11,462 | 4,413 | 124,409 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 18, 2016 | Option Exercise | $1.26 | 4,514 | 5,710 | 117,461 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 14, 2016 | Sale | $28.01 | 11,462 | 321,075 | 112,947 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 18, 2016 | Sale | $28.08 | 4,514 | 126,742 | 112,947 | Apr 18, 2016, 06:40 PM |
| Schatzman Randall C | President and CEO | Apr 15, 2016 | Sale | $28.11 | 14,024 | 394,150 | 112,947 | Apr 18, 2016, 06:40 PM |
| Benedict Larry | Sr. VP Finance | Nov 30, 2015 | Option Exercise | $8.50 | 2,000 | 17,000 | 28,247 | Feb 02, 2016, 07:00 PM |
| Litton Mark James | Chief Business Officer | Jan 04, 2016 | Option Exercise | $0.38 | 25,000 | 9,625 | 98,718 | Jan 06, 2016, 08:40 PM |
| Litton Mark James | Chief Business Officer | Jan 04, 2016 | Sale | $31.40 | 25,000 | 784,951 | 81,427 | Jan 06, 2016, 08:40 PM |
| Latham John A | Chief Scientific Officer | Jan 04, 2016 | Option Exercise | $1.26 | 10,000 | 12,650 | 251,726 | Jan 06, 2016, 08:37 PM |
| Latham John A | Chief Scientific Officer | Jan 04, 2016 | Sale | $31.41 | 10,000 | 314,137 | 245,226 | Jan 06, 2016, 08:37 PM |
| Schatzman Randall C | President and CEO | Jan 04, 2016 | Option Exercise | $0.38 | 10,000 | 3,850 | 121,579 | Jan 06, 2016, 08:35 PM |
| Schatzman Randall C | President and CEO | Jan 04, 2016 | Sale | $31.47 | 10,000 | 314,747 | 113,599 | Jan 06, 2016, 08:35 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2015 | Option Exercise | $0.38 | 4,272 | 1,645 | 4,272 | Dec 03, 2015, 09:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Dec 01, 2015 | Sale | $37.24 | 4,272 | 159,104 | 0 | Dec 03, 2015, 09:02 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2015 | Option Exercise | $0.38 | 4,550 | 1,752 | 246,276 | Dec 03, 2015, 09:00 PM |
| Latham John A | Chief Scientific Officer | Dec 01, 2015 | Sale | $37.24 | 4,550 | 169,452 | 241,726 | Dec 03, 2015, 09:00 PM |
| Schatzman Randall C | President and CEO | Dec 01, 2015 | Option Exercise | $0.38 | 10,000 | 3,850 | 121,579 | Dec 03, 2015, 08:59 PM |
| Schatzman Randall C | President and CEO | Dec 01, 2015 | Sale | $37.24 | 10,000 | 372,431 | 111,579 | Dec 03, 2015, 08:59 PM |
| DOW STEPHEN M | Director | Nov 30, 2015 | Sale | $37.11 | 88 | 3,266 | 0 | Dec 02, 2015, 05:56 PM |
| Latham John A | Chief Scientific Officer | Nov 02, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 245,810 | Nov 04, 2015, 09:44 PM |
| Latham John A | Chief Scientific Officer | Nov 02, 2015 | Sale | $33.69 | 4,545 | 153,137 | 244,410 | Nov 04, 2015, 09:44 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 02, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Nov 04, 2015, 09:42 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 02, 2015 | Sale | $33.67 | 3,900 | 131,299 | 2,400 | Nov 04, 2015, 09:42 PM |
| Schatzman Randall C | President and CEO | Nov 02, 2015 | Option Exercise | $0.38 | 10,000 | 3,850 | 119,921 | Nov 04, 2015, 09:40 PM |
| Schatzman Randall C | President and CEO | Nov 02, 2015 | Sale | $33.71 | 10,000 | 337,066 | 116,543 | Nov 04, 2015, 09:40 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 245,810 | Oct 05, 2015, 06:21 PM |
| Latham John A | Chief Scientific Officer | Oct 01, 2015 | Sale | $32.26 | 4,545 | 146,603 | 241,510 | Oct 05, 2015, 06:21 PM |
| Litton Mark James | Chief Business Officer | Oct 01, 2015 | Sale | $32.27 | 7,500 | 242,002 | 73,479 | Oct 05, 2015, 06:19 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Oct 05, 2015, 06:16 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Oct 01, 2015 | Sale | $32.25 | 3,900 | 125,778 | 100 | Oct 05, 2015, 06:16 PM |
| Benedict Larry | Sr. VP Finance | Sep 24, 2015 | Option Exercise | $3.28 | 24,981 | 82,060 | 26,247 | Sep 28, 2015, 06:19 PM |
| Latham John A | Chief Scientific Officer | Sep 24, 2015 | Option Exercise | $0.99 | 31,818 | 31,500 | 241,265 | Sep 28, 2015, 06:14 PM |
| Litton Mark James | Chief Business Officer | Sep 24, 2015 | Option Exercise | $1.26 | 12,764 | 16,146 | 80,419 | Sep 28, 2015, 06:11 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Sep 03, 2015, 06:09 PM |
| Latham John A | Chief Scientific Officer | Sep 01, 2015 | Sale | $38.52 | 4,545 | 175,059 | 210,347 | Sep 03, 2015, 06:09 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Sep 03, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Sep 01, 2015 | Sale | $38.50 | 3,900 | 150,165 | 1,500 | Sep 03, 2015, 06:01 PM |
| SRB Associates IX L.P. | Affiliate | Aug 31, 2015 | Sale | $38.75 | 16,218 | 628,460 | 88 | Sep 02, 2015, 02:51 PM |
| DOW STEPHEN M | Director | Aug 31, 2015 | Sale | $38.75 | 16,218 | 628,460 | 282,278 | Sep 02, 2015, 02:51 PM |
| SRB Associates IX L.P. | Affiliate | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 1,811,970 | Aug 13, 2015, 07:51 PM |
| SRB Associates IX L.P. | Affiliate | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 1,909,079 | Aug 13, 2015, 07:51 PM |
| JAGGERS JOHN V | Affiliate | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 1,909,125 | Aug 13, 2015, 07:50 PM |
| JAGGERS JOHN V | Affiliate | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 1,812,016 | Aug 13, 2015, 07:50 PM |
| DOW STEPHEN M | Director | Aug 11, 2015 | Sale | $40.40 | 115,358 | 4,660,763 | 2,183,205 | Aug 13, 2015, 07:49 PM |
| DOW STEPHEN M | Director | Aug 12, 2015 | Sale | $40.03 | 97,109 | 3,887,409 | 2,086,096 | Aug 13, 2015, 07:49 PM |
| Latham John A | Chief Scientific Officer | Aug 03, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Aug 05, 2015, 06:27 PM |
| Latham John A | Chief Scientific Officer | Aug 03, 2015 | Sale | $45.62 | 4,545 | 207,322 | 209,447 | Aug 05, 2015, 06:27 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 03, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Aug 05, 2015, 06:26 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Aug 03, 2015 | Sale | $45.64 | 3,900 | 178,003 | 0 | Aug 05, 2015, 06:26 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jul 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Jul 06, 2015, 06:05 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jul 01, 2015 | Sale | $51.18 | 3,900 | 199,616 | 0 | Jul 06, 2015, 06:05 PM |
| Latham John A | Chief Scientific Officer | Jul 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Jul 06, 2015, 06:02 PM |
| Latham John A | Chief Scientific Officer | Jul 01, 2015 | Sale | $51.13 | 4,545 | 232,381 | 209,447 | Jul 06, 2015, 06:02 PM |
| Litton Mark James | Chief Business Officer | Jul 01, 2015 | Sale | $51.10 | 7,500 | 383,219 | 67,655 | Jul 06, 2015, 05:59 PM |
| Benedict Larry | Sr. VP Finance | Jun 12, 2015 | Option Exercise | $1.65 | 25,454 | 41,999 | 26,720 | Jun 16, 2015, 06:15 PM |
| Benedict Larry | Sr. VP Finance | Jun 12, 2015 | Sale | $47.46 | 25,454 | 1,208,090 | 1,266 | Jun 16, 2015, 06:15 PM |
| Litton Mark James | Chief Business Officer | Jun 04, 2015 | Option Exercise | $0.38 | 25,000 | 9,625 | 100,155 | Jun 08, 2015, 07:05 PM |
| Litton Mark James | Chief Business Officer | Jun 04, 2015 | Sale | $44.27 | 25,000 | 1,106,853 | 75,155 | Jun 08, 2015, 07:05 PM |
| Latham John A | Chief Scientific Officer | Jun 04, 2015 | Option Exercise | $0.38 | 25,000 | 9,625 | 234,447 | Jun 08, 2015, 07:03 PM |
| Latham John A | Chief Scientific Officer | Jun 04, 2015 | Sale | $44.18 | 25,000 | 1,104,463 | 209,447 | Jun 08, 2015, 07:03 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Jun 03, 2015, 08:04 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jun 01, 2015 | Sale | $41.53 | 3,900 | 161,969 | 0 | Jun 03, 2015, 08:04 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,992 | Jun 03, 2015, 07:59 PM |
| Latham John A | Chief Scientific Officer | Jun 01, 2015 | Sale | $41.53 | 4,545 | 188,757 | 209,447 | Jun 03, 2015, 07:59 PM |
| Schatzman Randall C | President and CEO | May 26, 2015 | Option Exercise | $0.38 | 50,000 | 19,250 | 159,921 | May 28, 2015, 06:15 PM |
| Schatzman Randall C | President and CEO | May 26, 2015 | Sale | $38.96 | 50,000 | 1,948,085 | 109,921 | May 28, 2015, 06:15 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 21, 2015 | Option Exercise | $0.05 | 54,616 | 3,004 | 54,616 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 22, 2015 | Option Exercise | $0.05 | 7,202 | 396 | 7,202 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 21, 2015 | Sale | $38.92 | 54,616 | 2,125,496 | 0 | May 26, 2015, 07:53 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 22, 2015 | Sale | $38.47 | 7,202 | 277,027 | 0 | May 26, 2015, 07:53 PM |
| DOW STEPHEN M | Director | May 20, 2015 | Sale | $40.39 | 8,462 | 341,820 | 4,313,992 | May 21, 2015, 06:30 PM |
| Benedict Larry | Sr. VP Finance | May 19, 2015 | Option Exercise | $1.65 | 20,000 | 33,000 | 20,663 | May 21, 2015, 06:20 PM |
| Benedict Larry | Sr. VP Finance | May 19, 2015 | Sale | $38.86 | 20,000 | 777,196 | 663 | May 21, 2015, 06:20 PM |
| SRB Associates IX L.P. | 10% Owner | May 19, 2015 | Sale | $37.02 | 1,136,100 | 42,059,900 | 4,048,874 | May 21, 2015, 05:53 PM |
| DOW STEPHEN M | Director | May 21, 2015 | Sale | $65.69 | 20,000 | 1,313,846 | 314,203 | May 21, 2015, 03:34 PM |
| SIEGALL CLAY B | Director | May 14, 2015 | Option Exercise | $0.33 | 18,181 | 6,000 | 42,625 | May 18, 2015, 08:51 PM |
| SIEGALL CLAY B | Director | May 14, 2015 | Sale | $35.04 | 18,181 | 637,077 | 24,444 | May 18, 2015, 08:51 PM |
| SIEGALL CLAY B | Director | May 18, 2015 | Sale | $39.97 | 20,000 | 799,418 | 4,444 | May 18, 2015, 08:51 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | May 05, 2015, 06:22 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | May 01, 2015 | Sale | $25.67 | 3,900 | 100,130 | 0 | May 05, 2015, 06:22 PM |
| Latham John A | Chief Scientific Officer | May 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | May 05, 2015, 06:18 PM |
| Latham John A | Chief Scientific Officer | May 01, 2015 | Sale | $25.67 | 4,545 | 116,663 | 208,988 | May 05, 2015, 06:18 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Apr 01, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Apr 03, 2015, 06:02 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Apr 01, 2015 | Sale | $27.43 | 3,900 | 106,995 | 0 | Apr 03, 2015, 06:02 PM |
| Litton Mark James | Chief Business Officer | Apr 01, 2015 | Sale | $27.41 | 7,500 | 205,552 | 74,359 | Apr 03, 2015, 05:58 PM |
| Latham John A | Chief Scientific Officer | Mar 30, 2015 | Option Exercise | $0.38 | 14,500 | 5,582 | 223,488 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Apr 01, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Apr 01, 2015 | Sale | $27.42 | 4,545 | 124,609 | 208,988 | Apr 01, 2015, 08:36 PM |
| Latham John A | Chief Scientific Officer | Mar 30, 2015 | Sale | $30.20 | 14,500 | 437,909 | 208,988 | Apr 01, 2015, 08:36 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Mar 02, 2015 | Option Exercise | $0.38 | 3,900 | 1,501 | 3,900 | Mar 04, 2015, 05:35 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Mar 02, 2015 | Sale | $26.25 | 3,900 | 102,357 | 0 | Mar 04, 2015, 05:35 PM |
| Latham John A | Chief Scientific Officer | Mar 02, 2015 | Option Exercise | $0.38 | 4,545 | 1,750 | 213,533 | Mar 04, 2015, 05:32 PM |
| Latham John A | Chief Scientific Officer | Mar 02, 2015 | Sale | $26.26 | 4,545 | 119,340 | 208,988 | Mar 04, 2015, 05:32 PM |
| Benedict Larry | Sr. VP Finance | Nov 28, 2014 | Option Exercise | $8.50 | 663 | 5,636 | 663 | Jan 28, 2015, 06:09 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 26, 2015 | Option Exercise | $0.38 | 2,700 | 1,039 | 2,700 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 27, 2015 | Option Exercise | $0.38 | 1,200 | 462 | 1,200 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 26, 2015 | Sale | $27.89 | 2,700 | 75,316 | 0 | Jan 28, 2015, 06:01 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Jan 27, 2015 | Sale | $28.27 | 1,200 | 33,921 | 0 | Jan 28, 2015, 06:01 PM |
| Litton Mark James | Chief Business Officer | Jan 27, 2015 | Sale | $28.52 | 2,300 | 65,602 | 81,859 | Jan 28, 2015, 05:56 PM |
| Litton Mark James | Chief Business Officer | Jan 26, 2015 | Sale | $28.03 | 5,200 | 145,732 | 84,159 | Jan 28, 2015, 05:56 PM |
| Latham John A | Chief Scientific Officer | Jan 26, 2015 | Option Exercise | $0.38 | 7,900 | 3,041 | 216,888 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 27, 2015 | Option Exercise | $0.38 | 7,145 | 2,751 | 216,133 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 26, 2015 | Sale | $27.98 | 7,900 | 221,008 | 208,988 | Jan 28, 2015, 05:54 PM |
| Latham John A | Chief Scientific Officer | Jan 27, 2015 | Sale | $28.73 | 7,145 | 205,278 | 208,988 | Jan 28, 2015, 05:54 PM |
| Schatzman Randall C | President and CEO | Jan 27, 2015 | Sale | $28.71 | 63,578 | 1,825,165 | 109,921 | Jan 28, 2015, 05:51 PM |
| Schatzman Randall C | President and CEO | Jan 26, 2015 | Sale | $27.93 | 36,422 | 1,017,234 | 173,499 | Jan 28, 2015, 05:51 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 24, 2014 | Sale | $16.91 | 9,090 | 153,735 | 0 | Nov 25, 2014, 06:13 PM |
| Smith Jeffrey T L | Sr. VP Translational Medicine | Nov 21, 2014 | Sale | $15.71 | 20,000 | 314,118 | 9,090 | Nov 25, 2014, 06:13 PM |
| Litton Mark James | Chief Business Officer | Nov 20, 2014 | Sale | $15.63 | 30,000 | 469,011 | 88,484 | Nov 24, 2014, 06:37 PM |
| Delphi Management Partners VII, L.L.C. | 10% Owner | May 13, 2014 | Buy | $10.00 | 3,465 | 34,650 | 2,838,532 | May 15, 2014, 05:45 PM |
| Delphi Management Partners VII, L.L.C. | 10% Owner | May 13, 2014 | Buy | $10.00 | 346,535 | 3,465,350 | 2,835,067 | May 15, 2014, 05:45 PM |
| PAKIANATHAN DEEPIKA | Director | May 13, 2014 | Buy | $10.00 | 3,465 | 34,650 | 2,838,532 | May 15, 2014, 05:43 PM |
| PAKIANATHAN DEEPIKA | Director | May 13, 2014 | Buy | $10.00 | 346,535 | 3,465,350 | 2,835,067 | May 15, 2014, 05:43 PM |
| Montgomery Alan Bruce | Director | May 13, 2014 | Buy | $10.00 | 3,000 | 30,000 | 9,628 | May 15, 2014, 05:18 PM |
| Ventures West 8 Limited Partnership | 10% Owner | May 13, 2014 | Buy | $10.00 | 250,000 | 2,500,000 | 3,469,528 | May 15, 2014, 05:09 PM |
| Bridger Gary | Director | May 13, 2014 | Buy | $10.00 | 250,000 | 2,500,000 | 3,469,528 | May 15, 2014, 05:08 PM |
| Novo A/S | 10% Owner | May 13, 2014 | Buy | $10.00 | 550,000 | 5,500,000 | 3,201,183 | May 14, 2014, 04:24 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| STRECK PAUL | Chief Medical Officer | 10/11/2019 | 12,788 |
| STRECK PAUL | Chief Medical Officer | 10/22/2019 | 25,020 |
| Lavelle Erin | Chief Operating Officer | 10/22/2019 | 289,656 |
| Bucher James B | EVP & General Counsel | 10/11/2019 | 8,317 |
| Bucher James B | EVP & General Counsel | 05/31/2019 | 12,370 |
| Bucher James B | EVP & General Counsel | 10/22/2019 | 498,186 |
| Hassler Randal | EVP, Pharmaceutical Ops. | 10/22/2019 | 356,040 |
| Smith Jeffrey T L | Managing Director | 10/22/2019 | 387,036 |
| YARNO WENDY L | Director | 10/22/2019 | 90,000 |
| SIEGALL CLAY B | Director | 10/22/2019 | 570,852 |
| Montgomery Alan Bruce | Director | 10/22/2019 | 173,304 |
| Smith Jeffrey T L | Managing Director | 09/16/2019 | 135,902 |
| Smith Jeffrey T L | Managing Director | 09/16/2019 | 603,504 |
| Hassler Randal | EVP, Pharmaceutical Ops. | 04/25/2019 | 24,067 |
| Benedict Larry | EVP and PAO | 04/25/2019 | 23,662 |
| Smith Jeffrey T L | Managing Director | 04/25/2019 | 66,526 |
| Lavelle Erin | Chief Operating Officer | 04/25/2019 | 19,599 |
| Bucher James B | EVP & General Counsel | 04/25/2019 | 26,281 |
| Redmile Group, LLC | Director | 03/04/2019 | 19,999,995 |
| Latham John A | Chief Scientific Officer | 11/30/2018 | 4,553 |
| Bucher James B | EVP & General Counsel | 11/30/2018 | 2,553 |
| Benedict Larry | EVP and PAO | 11/30/2018 | 8,920 |
| Benedict Larry | EVP and PAO | 05/31/2018 | 12,333 |
| Smith Jeffrey T L | Managing Director | 12/03/2018 | 4,994 |
| Smith Jeffrey T L | Managing Director | 12/03/2018 | 69,826 |
| Bucher James B | Sr. VP & General Counsel | 05/31/2018 | 18,700 |
| Smith Jeffrey T L | Managing Director | 11/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 11/01/2018 | 67,637 |
| Latham John A | Chief Scientific Officer | 11/01/2018 | 227,954 |
| Latham John A | Chief Scientific Officer | 11/01/2018 | 335,589 |
| Smith Jeffrey T L | Managing Director | 10/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 10/01/2018 | 78,329 |
| Latham John A | Chief Scientific Officer | 10/01/2018 | 109,108 |
| Latham John A | Chief Scientific Officer | 10/01/2018 | 386,006 |
| Smith Jeffrey T L | Managing Director | 09/04/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 09/04/2018 | 90,699 |
| Latham John A | Chief Scientific Officer | 09/04/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 09/04/2018 | 449,680 |
| Smith Jeffrey T L | Managing Director | 08/01/2018 | 4,990 |
| Smith Jeffrey T L | Managing Director | 08/01/2018 | 98,489 |
| Latham John A | Chief Scientific Officer | 08/01/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 08/01/2018 | 488,768 |
| Smith Jeffrey T L | Managing Director | 07/02/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 07/02/2018 | 188,364 |
| Latham John A | Chief Scientific Officer | 07/02/2018 | 86,622 |
| Latham John A | Chief Scientific Officer | 07/02/2018 | 387,002 |
| Latham John A | Chief Scientific Officer | 06/01/2018 | 109,121 |
| Latham John A | Chief Scientific Officer | 06/01/2018 | 446,356 |
| Smith Jeffrey T L | Managing Director | 06/01/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 06/01/2018 | 217,127 |
| Litton Mark James | Chief Business Officer | 06/01/2018 | 22,500 |
| Litton Mark James | Chief Business Officer | 06/01/2018 | 405,412 |
| Smith Jeffrey T L | Managing Director | 05/16/2018 | 16,739 |
| Smith Jeffrey T L | Managing Director | 05/16/2018 | 182,758 |
| Latham John A | Chief Scientific Officer | 11/30/2017 | 4,413 |
| Latham John A | Chief Scientific Officer | 05/31/2017 | 4,359 |
| Bucher James B | Sr. VP & General Counsel | 11/30/2017 | 15,175 |
| Litton Mark James | Chief Business Officer | 11/13/2017 | 27,256 |
| Litton Mark James | Chief Business Officer | 11/13/2017 | 178,486 |
| SIEGALL CLAY B | Director | 11/01/2017 | 35,496 |
| Litton Mark James | Chief Business Officer | 10/16/2017 | 27,258 |
| Litton Mark James | Chief Business Officer | 10/16/2017 | 203,703 |
| YARNO WENDY L | Director | 07/18/2017 | 50,000 |
| DOW STEPHEN M | Director | 07/18/2017 | 250,000 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/20/2017 | 579 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/20/2017 | 11,700 |
| Schatzman Randall C | President and CEO | 02/09/2017 | 49,500 |
| Schatzman Randall C | President and CEO | 02/09/2017 | 750,756 |
| Benedict Larry | EVP and PAO | 11/30/2016 | 14,988 |
| Schatzman Randall C | President and CEO | 11/30/2016 | 8,161 |
| Litton Mark James | Chief Business Officer | 01/18/2017 | 2,472 |
| Litton Mark James | Chief Business Officer | 01/18/2017 | 34,599 |
| Litton Mark James | Chief Business Officer | 01/09/2017 | 825 |
| Litton Mark James | Chief Business Officer | 01/06/2017 | 9,113 |
| Litton Mark James | Chief Business Officer | 01/05/2017 | 2,803 |
| Litton Mark James | Chief Business Officer | 01/09/2017 | 11,500 |
| Litton Mark James | Chief Business Officer | 01/06/2017 | 156,520 |
| Litton Mark James | Chief Business Officer | 01/05/2017 | 50,972 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2016 | 68,328 |
| Latham John A | Chief Scientific Officer | 12/01/2016 | 5,999 |
| Latham John A | Chief Scientific Officer | 12/01/2016 | 82,812 |
| Latham John A | Chief Scientific Officer | 11/09/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 11/09/2016 | 301,839 |
| Schatzman Randall C | President and CEO | 11/07/2016 | 16,500 |
| Schatzman Randall C | President and CEO | 11/07/2016 | 251,605 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/01/2016 | 73,032 |
| Litton Mark James | Chief Business Officer | 10/17/2016 | 164,998 |
| Benedict Larry | EVP and PAO | 05/31/2016 | 17,000 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/03/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/03/2016 | 93,415 |
| Schatzman Randall C | President and CEO | 10/03/2016 | 10,349 |
| Schatzman Randall C | President and CEO | 10/03/2016 | 254,811 |
| Latham John A | Chief Scientific Officer | 10/03/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 10/03/2016 | 313,152 |
| Latham John A | Chief Scientific Officer | 09/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 09/01/2016 | 324,949 |
| Schatzman Randall C | President and CEO | 09/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 09/01/2016 | 324,820 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2016 | 97,483 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/15/2016 | 4,950 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/15/2016 | 93,512 |
| Schatzman Randall C | President and CEO | 08/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 08/01/2016 | 311,513 |
| Latham John A | Chief Scientific Officer | 08/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 08/01/2016 | 311,948 |
| Latham John A | Chief Scientific Officer | 07/26/2016 | 1,341 |
| Latham John A | Chief Scientific Officer | 07/27/2016 | 15,159 |
| Latham John A | Chief Scientific Officer | 07/26/2016 | 24,392 |
| Latham John A | Chief Scientific Officer | 07/27/2016 | 277,023 |
| Schatzman Randall C | President and CEO | 07/25/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 07/25/2016 | 280,805 |
| Litton Mark James | Chief Business Officer | 07/12/2016 | 9,625 |
| Litton Mark James | Chief Business Officer | 06/13/2016 | 173,664 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/03/2016 | 20,354 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/03/2016 | 485,933 |
| Schatzman Randall C | President and CEO | 06/01/2016 | 12,650 |
| Schatzman Randall C | President and CEO | 06/01/2016 | 296,544 |
| Latham John A | Chief Scientific Officer | 06/01/2016 | 16,500 |
| Latham John A | Chief Scientific Officer | 06/01/2016 | 300,216 |
| Latham John A | Chief Scientific Officer | 05/31/2016 | 46,003 |
| Latham John A | Chief Scientific Officer | 05/27/2016 | 8,097 |
| Latham John A | Chief Scientific Officer | 05/27/2016 | 192,335 |
| Latham John A | Chief Scientific Officer | 05/31/2016 | 1,009,284 |
| Litton Mark James | Chief Business Officer | 05/31/2016 | 7,592 |
| Litton Mark James | Chief Business Officer | 05/27/2016 | 2,033 |
| Litton Mark James | Chief Business Officer | 05/31/2016 | 592,566 |
| Litton Mark James | Chief Business Officer | 05/27/2016 | 158,693 |
| Schatzman Randall C | President and CEO | 05/23/2016 | 3,791 |
| Schatzman Randall C | President and CEO | 05/20/2016 | 3,777 |
| Schatzman Randall C | President and CEO | 05/24/2016 | 5,082 |
| Schatzman Randall C | President and CEO | 05/23/2016 | 83,952 |
| Schatzman Randall C | President and CEO | 05/20/2016 | 83,635 |
| Schatzman Randall C | President and CEO | 05/24/2016 | 112,588 |
| Schatzman Randall C | President and CEO | 04/15/2016 | 10,227 |
| Schatzman Randall C | President and CEO | 04/14/2016 | 4,413 |
| Schatzman Randall C | President and CEO | 04/18/2016 | 5,710 |
| Schatzman Randall C | President and CEO | 04/14/2016 | 321,075 |
| Schatzman Randall C | President and CEO | 04/18/2016 | 126,742 |
| Schatzman Randall C | President and CEO | 04/15/2016 | 394,150 |
| Benedict Larry | Sr. VP Finance | 11/30/2015 | 17,000 |
| Litton Mark James | Chief Business Officer | 01/04/2016 | 9,625 |
| Litton Mark James | Chief Business Officer | 01/04/2016 | 784,951 |
| Latham John A | Chief Scientific Officer | 01/04/2016 | 12,650 |
| Latham John A | Chief Scientific Officer | 01/04/2016 | 314,137 |
| Schatzman Randall C | President and CEO | 01/04/2016 | 3,850 |
| Schatzman Randall C | President and CEO | 01/04/2016 | 314,747 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2015 | 1,645 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 12/01/2015 | 159,104 |
| Latham John A | Chief Scientific Officer | 12/01/2015 | 1,752 |
| Latham John A | Chief Scientific Officer | 12/01/2015 | 169,452 |
| Schatzman Randall C | President and CEO | 12/01/2015 | 3,850 |
| Schatzman Randall C | President and CEO | 12/01/2015 | 372,431 |
| DOW STEPHEN M | Director | 11/30/2015 | 3,266 |
| Latham John A | Chief Scientific Officer | 11/02/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 11/02/2015 | 153,137 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/02/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/02/2015 | 131,299 |
| Schatzman Randall C | President and CEO | 11/02/2015 | 3,850 |
| Schatzman Randall C | President and CEO | 11/02/2015 | 337,066 |
| Latham John A | Chief Scientific Officer | 10/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 10/01/2015 | 146,603 |
| Litton Mark James | Chief Business Officer | 10/01/2015 | 242,002 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 10/01/2015 | 125,778 |
| Benedict Larry | Sr. VP Finance | 09/24/2015 | 82,060 |
| Latham John A | Chief Scientific Officer | 09/24/2015 | 31,500 |
| Litton Mark James | Chief Business Officer | 09/24/2015 | 16,146 |
| Latham John A | Chief Scientific Officer | 09/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 09/01/2015 | 175,059 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 09/01/2015 | 150,165 |
| SRB Associates IX L.P. | Affiliate | 08/31/2015 | 628,460 |
| DOW STEPHEN M | Director | 08/31/2015 | 628,460 |
| SRB Associates IX L.P. | Affiliate | 08/12/2015 | 3,887,409 |
| SRB Associates IX L.P. | Affiliate | 08/11/2015 | 4,660,763 |
| JAGGERS JOHN V | Affiliate | 08/11/2015 | 4,660,763 |
| JAGGERS JOHN V | Affiliate | 08/12/2015 | 3,887,409 |
| DOW STEPHEN M | Director | 08/11/2015 | 4,660,763 |
| DOW STEPHEN M | Director | 08/12/2015 | 3,887,409 |
| Latham John A | Chief Scientific Officer | 08/03/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 08/03/2015 | 207,322 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/03/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 08/03/2015 | 178,003 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 07/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 07/01/2015 | 199,616 |
| Latham John A | Chief Scientific Officer | 07/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 07/01/2015 | 232,381 |
| Litton Mark James | Chief Business Officer | 07/01/2015 | 383,219 |
| Benedict Larry | Sr. VP Finance | 06/12/2015 | 41,999 |
| Benedict Larry | Sr. VP Finance | 06/12/2015 | 1,208,090 |
| Litton Mark James | Chief Business Officer | 06/04/2015 | 9,625 |
| Litton Mark James | Chief Business Officer | 06/04/2015 | 1,106,853 |
| Latham John A | Chief Scientific Officer | 06/04/2015 | 9,625 |
| Latham John A | Chief Scientific Officer | 06/04/2015 | 1,104,463 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 06/01/2015 | 161,969 |
| Latham John A | Chief Scientific Officer | 06/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 06/01/2015 | 188,757 |
| Schatzman Randall C | President and CEO | 05/26/2015 | 19,250 |
| Schatzman Randall C | President and CEO | 05/26/2015 | 1,948,085 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/21/2015 | 3,004 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/22/2015 | 396 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/21/2015 | 2,125,496 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/22/2015 | 277,027 |
| DOW STEPHEN M | Director | 05/20/2015 | 341,820 |
| Benedict Larry | Sr. VP Finance | 05/19/2015 | 33,000 |
| Benedict Larry | Sr. VP Finance | 05/19/2015 | 777,196 |
| SRB Associates IX L.P. | 10% Owner | 05/19/2015 | 42,059,900 |
| DOW STEPHEN M | Director | 05/21/2015 | 1,313,846 |
| SIEGALL CLAY B | Director | 05/14/2015 | 6,000 |
| SIEGALL CLAY B | Director | 05/14/2015 | 637,077 |
| SIEGALL CLAY B | Director | 05/18/2015 | 799,418 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 05/01/2015 | 100,130 |
| Latham John A | Chief Scientific Officer | 05/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 05/01/2015 | 116,663 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 04/01/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 04/01/2015 | 106,995 |
| Litton Mark James | Chief Business Officer | 04/01/2015 | 205,552 |
| Latham John A | Chief Scientific Officer | 03/30/2015 | 5,582 |
| Latham John A | Chief Scientific Officer | 04/01/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 04/01/2015 | 124,609 |
| Latham John A | Chief Scientific Officer | 03/30/2015 | 437,909 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 03/02/2015 | 1,501 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 03/02/2015 | 102,357 |
| Latham John A | Chief Scientific Officer | 03/02/2015 | 1,750 |
| Latham John A | Chief Scientific Officer | 03/02/2015 | 119,340 |
| Benedict Larry | Sr. VP Finance | 11/28/2014 | 5,636 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/26/2015 | 1,039 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/27/2015 | 462 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/26/2015 | 75,316 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 01/27/2015 | 33,921 |
| Litton Mark James | Chief Business Officer | 01/27/2015 | 65,602 |
| Litton Mark James | Chief Business Officer | 01/26/2015 | 145,732 |
| Latham John A | Chief Scientific Officer | 01/26/2015 | 3,041 |
| Latham John A | Chief Scientific Officer | 01/27/2015 | 2,751 |
| Latham John A | Chief Scientific Officer | 01/26/2015 | 221,008 |
| Latham John A | Chief Scientific Officer | 01/27/2015 | 205,278 |
| Schatzman Randall C | President and CEO | 01/27/2015 | 1,825,165 |
| Schatzman Randall C | President and CEO | 01/26/2015 | 1,017,234 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/24/2014 | 153,735 |
| Smith Jeffrey T L | Sr. VP Translational Medicine | 11/21/2014 | 314,118 |
| Litton Mark James | Chief Business Officer | 11/20/2014 | 469,011 |
| Delphi Management Partners VII, L.L.C. | 10% Owner | 05/13/2014 | 34,650 |
| Delphi Management Partners VII, L.L.C. | 10% Owner | 05/13/2014 | 3,465,350 |
| PAKIANATHAN DEEPIKA | Director | 05/13/2014 | 34,650 |
| PAKIANATHAN DEEPIKA | Director | 05/13/2014 | 3,465,350 |
| Montgomery Alan Bruce | Director | 05/13/2014 | 30,000 |
| Ventures West 8 Limited Partnership | 10% Owner | 05/13/2014 | 2,500,000 |
| Bridger Gary | Director | 05/13/2014 | 2,500,000 |
| Novo A/S | 10% Owner | 05/13/2014 | 5,500,000 |
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR ALDER BIOPHARMACEUTICALS, INC.
LOADING...